Enhanced in vitro anticoagulant efficacy of factor XIa inhibitor asundexian, but not milvexian and abelacimab, in acutely ill patients with liver disease and in sepsis

milvexian (BMS-986177) - BMS, J&J

abelacimab (MAA868) - Anthos Therapeutics

asundexian (BAY 2433334) - Bayer

Fynn Elvers 1; Jelle Adelmeijer 1; Marilena Stamouli 2; William Bernal 2; Vishal Patel 2; Ton Lisman 1

May 25, 2026